Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models

International Journal of Molecular Medicine

Volumn 31, Issue 3, 2013, Pages 607-613

  Chen, Yan ^a   Li, Zhengyang ^a   Yang, Yan ^a   Lin, Lin ^a   Zhang, Hongjie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gastrointestinal motility; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Irritable bowel syndrome; Visceral hypersensitivity

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; COLON MOTILITY; COLON MUCOSA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RAT; FECES; IMMUNOHISTOCHEMISTRY; INTESTINE CONTRACTION; INTESTINE DISTENSION; IRRITABLE COLON; MALE; MYENTERIC PLEXUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WATER CONTENT;

ANIMALS; COLON; CONSTIPATION; DIARRHEA; DISEASE MODELS, ANIMAL; FECES; GLUCAGON-LIKE PEPTIDE 1; IRRITABLE BOWEL SYNDROME; MALE; MUSCLE CONTRACTION; PEPTIDES; PERISTALSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VENOMS; WATER;

EID: 84873124847     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1252     Document Type: Article

References (28)

1. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130: 1377-1390, 2006.
2. Clarke G, Quigley EM, Cryan JF and Dinan TG: Irritable bowel syndrome: towards biomarker identification. Trends Mol Med 15: 478-489, 2009.
3. Cremonini F and Talley NJ: Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 34: 189-204, 2005.
4. Spiller RC and Thompson WG: Bowel disorders. Am J Gastroenterol 105: 775-785, 2010.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.
6. Camilleri M, McKinzie S, Busciglio I, et al: Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6: 772-781, 2008.
7. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J and Schamby H: Clinical trial: the glucagon-like peptide-1 receptor agonist ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 29: 198-206, 2009.
8. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J and Marks V: Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138: 159-166, 1993.
9. Hellstrom PM, Naslund E, Edholm T, et al: GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 20: 649-659, 2008.
10. McDonagh SC, Lee J, Izzo A and Brubaker PL: Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine. Am J Physiol Gastrointest Liver Physiol 293: G461-G468, 2007.
11. Miki T, Minami K, Shinozaki H, et al: Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 54: 1056-1063, 2005.
12. Schirra J, Houck P, Wank U, Arnold R, Goke B and Katschinski M: Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46: 622-631, 2000.
13. Schirra J, Nicolaus M, Roggel R, et al: Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55: 243-251, 2006.
14. Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG and Mulè F: Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil 22: e664-e203, 2010.
15. Körner M, Stöckli M, Waser B and Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48: 736-743, 2007.
16. Peng LH, Yang YS, Sun G and Wang WF: A new model of Constipation- predominant irritable bowel syndrome in rats. Shijie Huaren Xiaohua Zazhi 12: 112-116, 2004 (In Chinese).
17. Williams CL, Villar RG, Peterson JM and Burks TF: Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology 94: 611-621, 1988.
18. Gui XY, Pan GZ and Ke MY: Residual effect of cold-restraint stress on colonic motility in rats. Chin J Dig Dis 17: 94-96, 1997 (In Chinese).
19. Habold C, Reichardt F, Le Maho Y, et al: Clay ingestion enhances intestinal triacylglycerol hydrolysis and non-esterified fatty acid absorption. Br J Nutr 102: 249-257, 2009.
20. Winston J, Shenoy M, Medley D, Naniwadekar A and Pasricha PJ: The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 132: 615-627, 2007.
21. Al-Chaer ED, Kawasaki M and Pasricha PJ: A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 119: 1276-1285, 2000.
22. Appleyard CB and Wallace JL: Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 269: G119-G125, 1995.
23. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25: 402-408, 2001.
24. Tolessa T, Gutniak M, Holst JJ, Efendic S and Hellstrom PM: Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43: 2284-2290, 1998.
25. Näslund E, Bogefors J, Skogar S, et al: GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277: R910-R916, 1999.
26. Nagell CF, Wettergren A, Ørskov C and Holst JJ: Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667-672, 2006.
27. Bozkurt A, Näslund E, Holst JJ and Hellström PM: GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul Pept 107: 129-135, 2002.
28. Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M and Greenberg GR: Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J Clin Endocrinol Metab 87: 3078-3083, 2002.